Blending Clinical Practice and Research: Forging Partnerships in the Great Lakes Region to Enhance Drug Addiction Treatment

This is Archived Content. This content is available for historical purposes only. It may not reflect the current state of science or language from the National Institute on Drug Abuse (NIDA).
View current meetings on


Detroit, Michigan


NIDA Clinical Trials Network

United States

Meeting Summary

2004 Meeting Overview:

The Blending Clinical Practice and Research: Forging Partnerships in the Great Lakes Region to Enhance Drug Addiction Treatment Meeting, held on September 27-28, 2004 in Detroit, Michigan, was presented by the National Institute on Drug Abuse (NIDA) and the Great Lakes Regional Node of the Clinical Trials Network (CTN) at Wayne State University, in conjunction with:

  • University of Michigan Addiction Research Center and Substance Abuse Section, Department of Psychiatry
  • Michigan State University
  • Michigan Office of Drug Control Policy, Department of Community Health
  • The City of Detroit
  • Great Lakes Addiction Technology Transfer Center
  • Psychiatry and Behavioral Medicine Professionals
  • Gateway Community Health

The conference brought together a variety of professionals and practitioners interested in the field of drug abuse and addiction medicine. It presented a great forum for individuals to discuss and explore current research, both through plenary presentations and interactive workshops.

The format consisted of two plenary presentations, covering the following topics:

  • Progress in Translating Drug Abuse Research into Clinical Practice - Nora D. Volkow, Ph.D.
  • Disease Management: Addiction as a Chronic Relapsing Disease - Thomas Carli, M.D.

The Eileen Pencer Memorial Lecture was delivered by Lawrence S. Brown, Jr., M.D., M.P.H., FASAM. The goal was to examine the application of science to clinical care, by reviewing what we have learned from current research, considerations for putting research to actual use, and steps for future research in the field.

This year also featured a panel discussion on Issues of Race and Ethnicity in Substance Abuse Treatment, which discussed the challenge of bringing empirically supported interventions to racial/ethnic minority clients in drug abuse treatment practice settings.


Meeting Day 1

Begin End Session Faculty
10:15 a.m. 11:45 a.m. Presentation Thomas Carli, M.D.
11:45 a.m. 12:30 p.m. Poster Session
12:30 p.m. 2:00 p.m. Afternoon Break
2:00 p.m. 4:30 p.m. Workshops 1-6
Methamphetamine: Epidemiology, Neurotoxicity, and Treatment Charles R. Schuster, Ph.D.
Chris-Ellyn Johanson, Ph.D.
Patricia Marinelli-Casey, Ph.D., MFT
Anna Talamo, M.A., MFT
Motivational Interviewing: What It Is, How It Works, and How To Make It Work in Your Agency William R. Miller, Ph.D.
Steven J. Ondersema, Ph.D.
Ned Snead, M.S.
Buprenorphine: From Basic Human Research to Clinical Application Mark Greenwald, Ph.D.
Walter Ling, M.D.
Virginia S. Ryan, Ph.D.
Allan J. Cohen, M.A., MFT
Transitions Across Stages and Levels of Drug Involvement James C. Anthony, Ph.D., M.Sc.
Richard Spoth, Ph.D.
Thomas Dishion, Ph.D.
Ty A. Ridenour, Ph.D., M.P.E.
Treatment on Demand: How It Has Affected the Cities of Baltimore, Detroit, Philadephia, and San Francisco Yvonne E. Anthony, Ph.D., M.B.A., M.H.A.
Calvin R. Trent, Jr., Ph.D., M.Ed.
Joseph Guydish, Ph.D., M.P.H.
Melisa M. Lindamood, M.P.S.
Mark Bencivengo, M.A.
Addressing Medical and Psychiatric Needs in Substance Abuse Treatment Michael R. Liepman, M.D.
Jeffrey Selzer, M.D.
John A. Hopper, M.D.
Kathleen A. Sheenan, M.S.N., R.N.
Anne C. Benion, M.S.S., ACSW

Meeting Day 2

Begin End Session Faculty
8:30 a.m. 9:45 a.m. Panel Discussion Jose Szapocznik, Ph.D.
Daniel A. Santisteban, Ph.D.
R. Dale Walker, M.D.
Lawrence S. Brown, Jr., M.D., M.P.H., FASAM
9:45 a.m. 10:00 a.m. Break
10:00 a.m. 12:30 p.m. Workshops 7-12
Behavioral Therapies in Substance Abuse Treatment: Contingency Management and Cognitive Behavioral Therapy Kathleen M. Carroll, Ph.D.
Maxine L. Stitzer, Ph.D.
Gary Rhodes, M.A., LLP
Co-Occuring Disorders in Substance Abuse Treatment Kathleen T. Brady, M.D., Ph.D.
Bruce Rounsaville, M.D.
Eric E. Schindler, Ph.D.
Women and Comorbidity Cynthia L. Arfken, Ph.D.
Sheryl Pimlott Kubiak, Ph.D., M.S.W.
Shelly F. Greenfield, M.D., M.P.H.
Susan M. Gordon, Ph.D.
Gloria M. Miele, Ph.D.
Treatment Interventions to Prevent the Next Generation of Substance Abuse: Family-Based Approaches Robert A. Zucker, Ph.D.
Deborah A. Ellis, Ph.D., M.A.
Karol Kumpfer, Ph.D.
Evidence-Based Practice: What it Means to the Provider Joseph Rosenfeld, Psy.D., CRADC
Lonnetta Albright
Steven L. Gallon, Ph.D.
Gregory S. Brigham, Ph.D.
Adjusting Intensity of Substance Abuse Treatment to Patient Need Robert K. Brooner, Ph.D.
Ron Jackson, M.S.W.
James R. McKay, Ph.D.
12:30 p.m. 2:00 p.m. Eileen Pencer Lecture Lawrence S. Brown, Jr., M.D., M.P.H., FASAM
2:00 p.m. Blending Conference Adjournment
2:00 p.m. 5:00 p.m. Mini-Courses
An Introduction to Motivational Interviewing Steven J. Ondersma, Ph.D.
Buprenorphine for the Treatment Team Susan M. Stine, M.D., Ph.D.
Laura F. McNicholas, M.D., Ph.D.
Albert L. Hasson, M.S.W.
Issues Related to HIV and Hepatitis C in Substance Abuse John A. Hopper, M.D.
Jeffrey Samet, M.D., M.A., M.P.H.
Best Practice in Addiction Treatment: How to Improve Skills as a Consumer of Research Lonnetta Albright
Steven L. Gallon, Ph.D.
Joseph Rosenfeld, Psy.D., CRADC
Wendy Hausotter, M.P.H.